NCT06381726 Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
| NCT ID | NCT06381726 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Milan |
| Condition | Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-03-07 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-03-07 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background Lower-grade-gliomas affect young patients, thus the longest progression-free-survival (PFS) with a high level quality of life is crucial. Surgery most significantly impacts on tumor natural history, postponing recurrence, improving symptoms, decreasing the need of adjuvant therapies, with extent of resection, gross-total and supra-total (GTR and STR), strongly associating with longest PFS. Achievement of GTR or STR depends on the degree of functional reorganization induced by glioma. Consequently, a successful treatment fostering neural circuit reorganization before surgery, would increase the chance of GRT/STR. Hypothesis The plastic potential of motor system suggests that reorganization of circuits controlling hand movements could be presurgically fostered in LGG patients by enhancing plasticity with up-front motor-rehabilitation and/or by decreasing tumor infiltration with up-front chemotherapy. Advanced neuroimaging allows to infer the neuroplasticity potential. Intraoperative assessment of the motor circuits functionality will validate reliability of preoperative analyses. Aims The project has 4 aims, investigating: A) the presurgical functional (FC) and structural (SC) connectomics of the hand-motor network to picture the spontaneous reorganization and the influence of clinical, imaging and histomolecular variables; B) the dynamic of FC and SC after tumor resection; C) changes in FC and SC maps after personalized upfront motor rehabilitation and/or chemotherapy; D) the effect of FC and SC upfront treatment on the achievement of GTR/STR preserving hand dexterity. Experimental Design Resting-state fMRI and diffusion-MRI will provide FC and SC maps pre- and post-surgery; personalized up-front motor rehabilitation and/or chemotherapy will be administered; Intraoperative brain mapping procedures will generate data to validate the maps. Expected Results 1. Provide a tool to render the motor functional reorganization predictive of surgical outcome. 2. Identify demographic, clinical and imaging variables associated with functional reorganization. 3. Describe the gain induced by up-front treatment. 4. Distinguish "patterns" predicting chance for GTR/STR from "patterns" suggesting need for up-front treatment. Impact On Cancer Results will increase the achievement of GTR/STR, preserving motor integrity, with dramatic impact on LGGs natural history.
Eligibility Criteria
Inclusion Criteria (ARM 1): * Patients signing informed consent for participation in the study * Males and females * Age ≥ 18 years * Patients with lower-grade gliomas with involvement of the motor pathways who are candidates for surgery Inclusion Criteria (ARM 2/3/4): * Patients signing informed consent for participation in the study * Males and females * Age ≥ 18 years * Patients with lower-grade gliomas treated over two years with tumors only biopsied and/or partially resected and eligible for second surgery Exclusion Criteria: * Age \<18 years * Inability to adhere to standard study controls * Subjects unable to understand and freely provide consent to the study
Contact & Investigator
Lorenzo Bello, MD
PRINCIPAL INVESTIGATOR
University of Milan
Frequently Asked Questions
Who can join the NCT06381726 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06381726 currently recruiting?
Yes, NCT06381726 is actively recruiting participants. Contact the research team at lorenzo.bello@unimi.it for enrollment information.
Where is the NCT06381726 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06381726 clinical trial?
NCT06381726 is sponsored by University of Milan. The principal investigator is Lorenzo Bello, MD at University of Milan. The trial plans to enroll 400 participants.